TRIM33 Reverses Cisplatin Resistance in Non-Small Cell Lung Cancer by Regulating the PI3K/AKT Pathway via Ubiquitination-Mediated Degradation of LPCAT1
Jie Huang, Bao Qing Wang, Qin Wu, Li Ming Wang, Chao Guan · 2026
Read TRIM33 Reverses Cisplatin Resistance in Non-Small Cell Lung Cancer by Regulating the PI3K/AKT Pathway via Ubiquitination-Mediated Degradation of LPCAT1 by Jie Huang, Bao Qing Wang, Qin Wu, Li Ming Wang, Chao Guan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13171270.txt.
Description
Jie Huang and four co-authors show how a regulatory protein can restore drug sensitivity in lung cancer, in a study from 2026. A first-line chemotherapy drug often fails as tumors grow resistant. A fat-processing enzyme aids tumor growth, but its role in resistance was unclear.
They built resistant lung cancer cell lines by slow dose escalation and measured growth, energy use, and death. The regulator binds the enzyme and tags it for disposal, which damps a key growth pathway. In dishes and mouse tumors, restoring the regulator curbed the enzyme and revived drug response. Blocking the disposal step reversed the effect.
Catalog record
| CREATOR | Jie Huang, Bao Qing Wang, Qin Wu, Li Ming Wang, Chao Guan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |